Erasca, Inc.
ERAS
Kedudukan dalam Saham
#3565
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Harga Saham
$13.68
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$4.78B
Perubahan (1 hari)
2.13%
Perubahan (1 tahun)
455.89%
Negara
US
Perdagangan Erasca, Inc. (ERAS)
Kategori
Healthcare
Nisbah P/B bagi Erasca, Inc. (ERAS)
Nisbah P/B pada October 2026 TTM: 12.65
Menurut laporan kewangan dan harga saham terkini Erasca, Inc., nisbah P/B semasa (TTM) ialah 12.65. Pada akhir 2023, nisbah P/B syarikat ialah 1.01.
Sejarah nisbah P/B untuk Erasca, Inc. dari 2019 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 12.65 | 809.88% |
| 2024 | 1.39 | 37.19% |
| 2023 | 1.01 | -20.90% |
| 2022 | 1.28 | -68.58% |
| 2021 | 4.06 | -122.34% |
| 2020 | -18.19 | -88.07% |
| 2019 | -152.41 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | -50.57% |
US
|
|
| 13.2547 | 4.80% |
US
|
|
| 4.208 | -66.73% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -51.12% |
NL
|
